Skip to content

Verification of the effect of lubiprostone on intestinal permeability in healthy volunteers

Verification of the effect of lubiprostone on intestinal permeability in healthy volunteers - Verification of the effect of lubiprostone on intestinal permeability in healthy volunteers

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000017342
Enrollment
35
Registered
2015-05-01
Start date
2015-05-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Interventions

24mcg of Lubiprostone once daily after lunch for 14 days or 28 days No treatment for 14 days or 28 days

Sponsors

Yokohama City University School of Medicine Department of Gastroenterology and Hepatology
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1)Men at age >=20 years but <60 years when the consent was obtained 2)Persons who were determined to be healthy adults by the investigator/sub-investigator (hereinafter referred to as investigator, etc.) during medical interview at screening 3)Persons from whom the written consent was obtained and who can abide by the compliance rules while participating in this study, receive medical examination and tests prescribed in this protocol, and report symptoms, etc.

Exclusion criteria

Exclusion criteria: 1)Persons who have received NSAIDs within 3 months before obtaining the consent (excluding topical administration of NSAIDs) 2)Persons with history of food or drug allergy (diclofenac sodium, lubiprostone, etc.) or who are suspected of such allergy 3)Persons with current or history of serious cardiovascular/vascular, hematological, respiratory, liver, kidney, gastrointestinal, or neuropsychiatric disease 4)Persons who are taking proton pump inhibitors (PPIs), antibiotics, or intestinal drugs (excluding topical administration of antibiotics) 5)Persons who have participated in other clinical studies and received the study drug, etc. within 1 month prior to the start of this study (calculated from the administration date of the study drug) 6)Persons who were judged by the investigator, etc. to be inappropriate as a subject for this study

Design outcomes

Primary

MeasureTime frame
Permeability of the small intestine using the lactulose/mannitol test

Secondary

MeasureTime frame
Endotoxin activity in blood, changes in the intestinal flora

Countries

Japan

Contacts

Public ContactHiroki Endo

Yokohama City University Department of Gastroenterology and Hepatology

endo1978@yokohama-cu.ac.jp045-787-2800ext.6600

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026